Boehringer Ingelheim Pharma GmbH & Co. KG

Industry / private company


Location: Ingelheim am Rhein, Germany (DE) DE

ISNI: 0000000121717500

ROR: https://ror.org/00q32j219

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases (2019) Matteson E, Kelly C, Distler J, Mann-Vold AMH, Seibold J, Mittoo S, Distler O, et al. Conference contribution The Effect of Nintedanib versus Mycopheolate Mofetil in the FRA2 Mouse Model of Systemic Sclerosis Associated Interstitial Lung Disease (2019) Thuong Trin-Minh , Zhang Y, Distler J, Wollin L Conference contribution A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours (2019) Krauss J, Eigentler T, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, et al. Conference contribution Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases (2019) Wollin L, Distler J, Redente EF, Riches DW, Stowasser S, Schlenker-Herceg R, Maher TM, Kolb M Journal article, Review article A Comparison of Job Stress Models: Associations with Employee Well-Being, Absenteeism, Presenteeism, and Resulting Costs (2019) Schmidt B, Schneider M, Seeger P, Van Vianen A, Loerbroks A, Herr RM Journal article Dabigatran for prevention of stroke after embolic stroke of undetermined source (2019) Diener HC, Sacco RL, Donald Easton J, Granger CB, Bernstein RA, Uchiyama S, Kreuzer J, et al. Journal article FROM BENCH TO BEDSIDE: NINTEDANIB FOR PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES (2019) Wollin L, Distler J, Redente E, Riches D, Stowasser S, Schlenker-Herceg R Conference contribution Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis–associated interstitial lung disease (2019) Wollin L, Distler J, Denton CP, Gahlemann M Journal article, Review article Extending the time window for intravenous thrombolysis in acute ischemic stroke using magnetic resonance imaging-based patient selection (2019) Ringleb P, Bendszus M, Bluhmki E, Donnan G, Eschenfelder C, Fatar M, Kessler C, et al. Journal article Noelin1 Affects Lateral Mobility of Synaptic AMPA Receptors (2018) Pandya NJ, Seeger C, Babai N, Gonzalez-Lozano MA, Mack V, Lodder JC, Gouwenberg Y, et al. Journal article